HARPOON THERAPEUTICS ANNOUNCES PRELIMINARY SAFETY AND PHARMACOLOGY DATA FROM ITS HPN424 PHASE 1 TRIAL IN PROSTATE CANCER Initial data shows HPN424 serum exposure supports weekly dosing Changes in blood-derived tumor cell and serum biomarkers consistent with T cell...
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia December 03, 2018 Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects...
Kit Check Announces “Works with Kit Check” Certification Program for Hospital Pharmacy Vendors Ava MutchlerDecember 3, 2018 The program, which includes nine launch partners, provides assurance of Kit Check compatibility with hospital solutions ANAHEIM, CA (December 3,...
Kit Check Closes the Diversion Gap with Launch of Bluesight IRIS and Reveals Which Hospital Employees Exhibit Behaviors Consistent with Controlled Substance Theft Ava Mutchler Leading Automated Medication Solutions Provider for Hospital Pharmacies Leverages Machine...
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company -Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer-...
Recent Comments